ABT — Abbott Laboratories

Analyst consensus is Buy (32 buy, 9 hold, 0 sell) with a $123.64 average target, and the live research brief describes sentiment as moderately bullish. Q2 2026 adjusted EPS of $1.31 beat the $1.28 consensus, management raised full-year adjusted EPS guidance to $5.45–$5.60, and recent FDA De Novo authorization for Libre Duo 10 Day plus CE Mark for Amulet 360 added positive product momentum. The day's 2.2% pullback and continued Exact Sciences integration keep sentiment from being exuberant.

The revenue trend is inflecting upward, but the GAAP earnings path is noisy. Quarterly revenue rose from $10.36B in Q1 2025 to $11.14B, $11.37B, $11.46B, then $11.16B in Q1 2026 and $12.59B in Q2 2026 — Q2 2026 was up 13.0% reported versus the prior year, though only 4.8% organic, with Exact Sciences consolidation boosting the reported number. GAAP operating margin compressed from 18.4% in Q2 2025 to 14.2% in Q2 2026, and GAAP EPS dropped from $1.01 to $0.53, driven largely by acquisition/amortization and one-off items. Management's adjusted EPS of $1.31 and raised guidance show the underlying business is healthy; the 2024 Q4 GAAP EPS of $5.27 was a one-off tax/gain item and should be ignored for trend analysis.

On trailing GAAP numbers, ABT looks expensive at 35.9x TTM P/E, but that multiple is distorted by the Exact Sciences acquisition and the 2024 Q4 one-off gain. The more relevant forward adjusted multiple is about 20.2x based on the $111.56 price divided by the $5.517 estimated forward EPS. Price-to-sales of 4.14x is below ABT's 5-year average of 4.91x, and the 2.78% dividend yield adds support. This is a fair-to-slightly-cheap valuation versus its own history, not a deep-value situation.

At $111.56 as of 2026-08-27, the stock is pricing in a successful Exact Sciences integration, mid-single-digit organic growth, and continued MedTech strength — but not a hyper-growth scenario. If Libre Duo 10 Day ramps quickly and Amulet 360 gains traction in Europe, earnings revisions toward the $5.60–$5.70 area would support a move into the $120–$125 range. If integration stumbles or litigation costs escalate, the first downside reference is roughly the 200-day SMA near $107, then the 50-day SMA near $102.

As of 2026-08-27, RSI stood at 57.5, price was 0.6% above the 20-day SMA, 9.4% above the 50-day SMA, and 4.4% above the 200-day SMA. The trend is up and momentum is mid-range, but the day's 2.2% drop from a prior close of $114.10 signals a short-term pullback off resistance. This is not an oversold entry setup; better risk/reward would come on a dip toward the $107–$110 zone.

• Defensive rotation into large-cap healthcare is supporting ABT as sticky inflation and a divided Fed keep macro uncertainty elevated.
• Interest rates remain a crosscurrent: higher rates discount future MedTech growth, but ABT's stable cash flows and 2.8% dividend make it a relative shelter.
• CGM competition is intense, especially from Dexcom, though Abbott's category-first approvals and Medicare reimbursement push are structural tailwinds.
• Regulatory momentum from FDA and CE Mark approvals is favorable for new device adoption.
• Infant formula litigation remains a headline risk, though recent partial settlements reduce tail-risk sentiment.

• Q3 2026 earnings expected mid-to-late October 2026, with initial Libre Duo 10 Day commercial traction in focus.
• Commercial rollout of Amulet 360 in Europe after its CE Mark.
• Exact Sciences integration milestones, cost synergies, and deleveraging progress.
• Further resolutions of infant formula litigation that could remove an overhang.

• CGM share loss or pricing pressure versus Dexcom and other competitors.
• Unresolved infant formula litigation could produce larger-than-expected settlements.
• Integration and leverage risk from the Exact Sciences acquisition, including goodwill impairment or slower-than-expected synergies.
• Regulatory or quality issues with new devices could delay launches.
• Macro risks including FX, China slowdown, and reimbursement pressure in medical devices.

ABT is a high-quality defensive compounder with improving product momentum, a 54-year dividend streak, and a growing MedTech franchise. At $111.56, however, you are paying roughly fair value for that quality — not a bargain — so the stock is a reasonable long-term holding for income-focused investors but less compelling as a high-return growth trade; a pullback toward $105–$107 would improve the risk/reward.

Theoretical fair value is calculated by applying a 21.5x forward adjusted P/E to the $5.517 estimated forward EPS, a reasonable multiple for a defensive, dividend-growing MedTech leader with ~7% organic growth and a low beta; this yields approximately $118.6 and sits just below the analyst consensus target, reflecting a fair but not stretched valuation.